American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 1029-1032 , June 2008

Use of Circulating Antiangiogenic Factors to Differentiate Other Hypertensive Disorders From Preeclampsia in a Pregnant Woman on Dialysis

  • Hui Yi Shan, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
    • ,
  • Sarosh Rana, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Women and Infants Hospital, Providence, RI
    • ,
  • Franklin H. Epstein, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
    • ,
  • Isaac E. Stillman, MD

      Affiliations

    • Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
    • ,
  • S. Ananth Karumanchi, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
    • Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
    • Corresponding Author InformationAddress correspondence to S. Ananth Karumanchi, MD, Beth Israel Deaconess Medical Center, 330 Brookline Ave, RW 663B, Boston, MA 02215.
    • ,
  • Mark E. Williams, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

Received 20 December 2007 ,Revised 20 February 2008

References 

  1. Holley JL, Reddy SS. Pregnancy in dialysis patients: A review of outcomes, complications, and management. Semin Dial. 2003;16:384–388
  2. Hou S. Pregnancy in dialysis patients: Where do we go from here?. Semin Dial. 2003;16:376–378
  3. Shemin D. Dialysis in pregnant women with chronic kidney disease. Semin Dial. 2003;16:379–383
  4. Hou S. Modification of dialysis regimens for pregnancy. J Artif Organs. 2002;25:823–826
  5. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649
  6. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658
  7. Levine RJ, Chun L, Cong Q, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005
  8. Levine RJ, Maynard SE, Cong Q, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  9. Brown MA. Which factors affect the resolution of hypertensive pregnancy disorders after delivery?. Nat Clin Pract Nephrol. 2006;2:476–477
  10. Salahuddin S, Lee Y, Karumanchi SA, et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197:e1–e6
  11. English Operator's Manual. Polyflux H. Hechingen, Germany, Gambro Dialysatoren GmbH, 2007
  12. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;15:10705–10709

 Originally published online as doi:10.1053/j.ajkd.2008.03.011 on April 30, 2008.

PII: S0272-6386(08)00588-X

doi: 10.1053/j.ajkd.2008.03.011

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 1029-1032 , June 2008

Article Tools

* Image Usage & Resolution